Cramer's Mad Money - The Unsinkable Biogen IDEC (1/8/13)

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday January 8.

CEO Interview: George Sangos, Biogen IDEC (BIIB)

A recent clinical trial that ended in disappointment didn't bring Biogen IDEC (BIIB) down; the stock barely budged after the lackluster data were released. One reason BIIB's shares held firm is that Biogen has many other things going its way, including 2 major drugs for Multiple Sclerosis and one additional drug on the way that can be administered orally and not through injection. When Cramer asked CEO George Sangos if this new MS drug could take market share away from BIIB's other drugs, Sangos explained that there is enough diversification among patients and physicians in attitudes and needs during treatment that there will be sufficient demand for all three drugs. Currently, BIIB has 30% market share in the MS treatment market. BIIB is developing what is hoped to be the top drug to treat hemophilia, and will entail fewer injections for hemophilia sufferers than are required under current treatment programs. READ FULL ARTICLE HERE

Posted in and tagged with
.

Why Open a Browser, get citybizlist in your InBox.